A Blank Rome team represented Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, in its securities purchase agreement with institutional investors with the potential to raise up to $104.5 million in gross proceeds, including initial upfront funding of $16.5 million and up to an additional $88.0 million upon the potential cash exercise of accompanying warrants at the election of the investors. The private placement was priced at a premium to the Company’s prior day’s closing stock price.
The financing includes participation from new healthcare-focused investors, including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others. Maxim Group LLC is acted as sole placement agent for the private placement.
Quoin intends to use the upfront net proceeds from the private placement for general corporate purposes, which may include operating expenses, research and development, working capital, future acquisitions, and general capital expenditures.
For more information about this financing, please read the press release: Quoin Pharmaceuticals Announces Private Placement Financing (October 10, 2025).
The Blank Rome team was led by Peter I. Tsoflias and Melissa Palat Murawsky, with assistance from Leslie Marlow, Thomas E. Carroll and Christy Grzan.
